AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27339864 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion of parasitemic whole blood (WB) units
Number of subjects: 37
Study 25708531 — intervention group
Group type: EXPERIMENTAL
Intervention: Cal/BD foam
Number of subjects: 24
Study 25708531 — intervention group
Group type: COMPARATOR
Intervention: Cal/BD ointment
Number of subjects: 24
Study 25708531 — intervention group
Group type: COMPARATOR
Intervention: BD foam
Number of subjects: 24
Study 25708531 — intervention group
Group type: COMPARATOR
Intervention: Foam vehicle
Number of subjects: 24
Study 24088075 — intervention group
Group type: EXPERIMENTAL
Intervention: V7 (10 µg heat-killed Mycobacterium vaccae)
Number of subjects: 41
Study 24088075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 21045188 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 13
Study 21045188 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 13
Study 18718871 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid mixture designed to deplete plasma tryptophan
Number of subjects: 0
Study 18718871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16054286 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of labour
Number of subjects: 33
Study 16054286 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 33
Study 14514588 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 (120 pmol x kg(‐1). h(‐1) for 12 weeks)
Number of subjects: 16
Study 14514588 — intervention group
Group type: COMPARATOR
Intervention: Usual glucose-lowering therapy
Number of subjects: 16
Study 14514588 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1
Number of subjects: 16
Study 10908083 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine extended release (ER)
Number of subjects: 450
Study 10908083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study 8969731 — intervention group
Group type: EXPERIMENTAL
Intervention: Pause in rhGH therapy (group 1) for a mean duration of 25.5 +/- 26.9 months.
Number of subjects: 52
Study 8969731 — intervention group
Group type: EXPERIMENTAL
Intervention: Resumption of rhGH therapy after a pause (group 2) for a mean duration of 9.0 +/- 4.6 months.
Number of subjects: 52
Study 8969731 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation of rhGH therapy at the time of transplantation (30 patients).
Number of subjects: 52
Study 8969731 — intervention group
Group type: COMPARATOR
Intervention: Post-transplantation growth velocity after discontinuation of rhGH therapy.
Number of subjects: 52
Study 8969731 — intervention group
Group type: COMPARATOR
Intervention: Delta height SDS at last follow-up after discontinuation of rhGH therapy.
Number of subjects: 52
Study 1471603 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-receptor antagonists
Number of subjects: 0
Study 1471603 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 1471603 — intervention group
Group type: COMPARATOR
Intervention: Thiazide diuretics
Number of subjects: 0
Study 1471603 — intervention group
Group type: COMPARATOR
Intervention: Calcium antagonists
Number of subjects: 0
Study 1471603 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin-converting enzyme inhibitors
Number of subjects: 0
Study 6327758 — intervention group
Group type: EXPERIMENTAL
Intervention: RU 486 (400 mg)
Number of subjects: 0
Study 6327758 — intervention group
Group type: EXPERIMENTAL
Intervention: RU 486 (200 mg)
Number of subjects: 0
Study 6327758 — intervention group
Group type: COMPARATOR
Intervention: RU 486 (400 mg) at 1400 h
Number of subjects: 0
Study 6327758 — intervention group
Group type: EXPERIMENTAL
Intervention: RU 486 (400 mg) with dexamethasone (1 mg) at 2400 h
Number of subjects: 0
Study 28820651 — intervention group
Group type: EXPERIMENTAL
Intervention: Rear mounted powered drive wheel
Number of subjects: 24
Study 29216922 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactic-fermented egg white (LE)
Number of subjects: 37
Study 29216922 — intervention group
Group type: COMPARATOR
Intervention: Control (whey)
Number of subjects: 37
Study 25417935 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducative group intervention with relaxation (n=131; six sessions during pregnancy, one postnatal)
Number of subjects: 371
Study 25417935 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducative group intervention with relaxation (n=131)
Number of subjects: 371
Study 25417935 — intervention group
Group type: COMPARATOR
Intervention: Conventional care (n=240)
Number of subjects: 371
Study 24350806 — intervention group
Group type: EXPERIMENTAL
Intervention: Home telemonitoring of blood glucose and blood pressure
Number of subjects: 108
Study 21981375 — intervention group
Group type: EXPERIMENTAL
Intervention: CS20 protective barrier gel
Number of subjects: 106
Study 21981375 — intervention group
Group type: COMPARATOR
Intervention: Topical aciclovir
Number of subjects: 106
Study 19030969 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Gp IIb‐IIIa inhibitors
Number of subjects: 1662
Study 17726080 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate, high-fat (LCHF) diet
Number of subjects: 18
Study 17726080 — intervention group
Group type: COMPARATOR
Intervention: Low-fat, high-carbohydrate (LFHC) diet
Number of subjects: 18
Study 15224023 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold blood cardioplegia with a hot shot
Number of subjects: 103
Study 15224023 — intervention group
Group type: COMPARATOR
Intervention: Cold crystalloid cardioplegia
Number of subjects: 103
Study 15224023 — intervention group
Group type: COMPARATOR
Intervention: Cold blood cardioplegia
Number of subjects: 103
Study 15922817 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine maleate
Number of subjects: 118
Study 15922817 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine besylate
Number of subjects: 118
Study 10484301 — intervention group
Group type: EXPERIMENTAL
Intervention: Lap-Band operation
Number of subjects: 39
Study 8767776 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem SR (120 mgs bid)
Number of subjects: 48
Study 8767776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 1909273 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon treatment
Number of subjects: 28
Study 1909273 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated patients)
Number of subjects: 28
Study 6759647 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlormezanone
Number of subjects: 10
Study 31376908 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (15 mg daily)
Number of subjects: 3250
Study 31376908 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (placebo or acetylsalicylic acid 100 mg daily)
Number of subjects: 3250
Study 29414618 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Anesthesia (SA)
Number of subjects: 40
Study 29414618 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 40
Study 27121793 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine plus irinotecan (CAPIRI) therapy
Number of subjects: 183
Study 27121793 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine monotherapy
Number of subjects: 183
Study 27121793 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable (general finding)
Number of subjects: 183
Study 24717890 — intervention group
Group type: EXPERIMENTAL
Intervention: Spreader flap technique
Number of subjects: 66
Study 24717890 — intervention group
Group type: COMPARATOR
Intervention: Control group (no spreader flap)
Number of subjects: 66
Study 21607554 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel-based doublet
Number of subjects: 2126
Study 21607554 — intervention group
Group type: COMPARATOR
Intervention: Single-agent docetaxel
Number of subjects: 2126
Study 20716839 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi training (supervised once a week and home-based three times a week for one year)
Number of subjects: 20
Study 20716839 — intervention group
Group type: COMPARATOR
Intervention: Conventional cardiac rehabilitation only
Number of subjects: 20
Study 18341819 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive autoantibodies against AT(1)-receptor
Number of subjects: 592
Study 18341819 — intervention group
Group type: COMPARATOR
Intervention: Negative autoantibodies against AT(1)-receptor
Number of subjects: 592
Study 16343101 — intervention group
Group type: COMPARATOR
Intervention: Resistance training exercise, three times/week for 1 h/session (n = 65)
Number of subjects: 207
Study 16343101 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi, three times/week for 1 h/session (n = 64)
Number of subjects: 207
Study 16343101 — intervention group
Group type: COMPARATOR
Intervention: Usual level of physical activity control group (n = 78)
Number of subjects: 207
Study 11870488 — intervention group
Group type: EXPERIMENTAL
Intervention: iodixanol 320 mgI/ml
Number of subjects: 315
Study 11870488 — intervention group
Group type: EXPERIMENTAL
Intervention: iodixanol 270 mgI/ml
Number of subjects: 315
Study 11870488 — intervention group
Group type: COMPARATOR
Intervention: iotrolan 300 mgI/ml
Number of subjects: 315
Study 11382891 — intervention group
Group type: EXPERIMENTAL
Intervention: 48 hours sleep deprivation
Number of subjects: 16
Study 11382891 — intervention group
Group type: COMPARATOR
Intervention: Regular sleep schedule (Control)
Number of subjects: 16
Study 7787395 — intervention group
Group type: EXPERIMENTAL
Intervention: Astragalus membranaceus (AM)
Number of subjects: 92
Study 7787395 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 92
Study 7787395 — intervention group
Group type: COMPARATOR
Intervention: Tab. Salviae miltiorrhizae
Number of subjects: 92
Study 31876594 — intervention group
Group type: EXPERIMENTAL
Intervention: TAF/FTC+DTG
Number of subjects: 48
Study 31876594 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF/FTC+DTG
Number of subjects: 48
Study 31876594 — intervention group
Group type: COMPARATOR
Intervention: TDF/FTC/EFV
Number of subjects: 48
Study 31446510 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pathway treatment (n=17)
Number of subjects: 32
Study 31446510 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=15)
Number of subjects: 32
Study 27367794 — intervention group
Group type: EXPERIMENTAL
Intervention: Branched-chain amino acids (BCAA), arginine, and citrulline (0.17 g/kg BCAA, 0.05 g/kg arginine, 0.05 g/kg citrulline)
Number of subjects: 9
Study 27367794 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PB trial)
Number of subjects: 9
Study 27367794 — intervention group
Group type: EXPERIMENTAL
Intervention: Branched-chain amino acids (BCAA), arginine, and citrulline
Number of subjects: 9
Study 26516908 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligofructose-enriched inulin (5 g)
Number of subjects: 47
Study 26516908 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 47
Study 23238663 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (1.8 g eicosapentaenoic acid and 1.5 g docosahexaenoic acid)
Number of subjects: 45
Study 23238663 — intervention group
Group type: COMPARATOR
Intervention: Identical olive oil capsules (placebo)
Number of subjects: 45
Study 23238663 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids
Number of subjects: 45
Study 21870665 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychogenic illness induction group
Number of subjects: 0
Study 21870665 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychogenic illness induction plus media group
Number of subjects: 0
Study 21870665 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control group
Number of subjects: 0
Study 17625310 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous regional arterial infusion of a protease inhibitor
Number of subjects: 0
Study 17625310 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 16273634 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE-PEI
Number of subjects: 52
Study 16273634 — intervention group
Group type: COMPARATOR
Intervention: TACE
Number of subjects: 52
Study 11792410 — intervention group
Group type: EXPERIMENTAL
Intervention: MEP regimen
Number of subjects: 49
Study 11792410 — intervention group
Group type: EXPERIMENTAL
Intervention: C-MEP regimen
Number of subjects: 49
Study 10626026 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot study for asbestos-exposed workers
Number of subjects: 0
Study 10626026 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot study for smokers
Number of subjects: 0
Study 10626026 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline predictors for asbestos-exposed participants
Number of subjects: 0
Study 10626026 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline predictors for smoker participants
Number of subjects: 0
Study 10626026 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for inactivity
Number of subjects: 0
Study 7485849 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 72
Study 7485849 — intervention group
Group type: COMPARATOR
Intervention: No alcohol
Number of subjects: 72
Study 7485849 — intervention group
Group type: COMPARATOR
Intervention: Active placebo beverage
Number of subjects: 72
Study 1657506 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg of aspirin daily in the morning
Number of subjects: 0
Study 1657506 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg of aspirin four times a day
Number of subjects: 0
Study 1657506 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (both doses)
Number of subjects: 0
Study 1657506 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (600 mg four times a day)
Number of subjects: 0
Study 1657506 — intervention group
Group type: COMPARATOR
Intervention: Enteric coating of aspirin
Number of subjects: 0
Study 6800636 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervoltage radiotherapy with one fractionation scheme
Number of subjects: 0
Study 6800636 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervoltage radiotherapy with another fractionation scheme
Number of subjects: 0
Study 6800636 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31515735 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 207
Study 31515735 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 207
Study 30882683 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-tunnel ACL double-bundle anatomic reconstruction
Number of subjects: 58
Study 30882683 — intervention group
Group type: COMPARATOR
Intervention: Double-tunnel ACL double-bundle anatomic reconstruction
Number of subjects: 58
Study 30012822 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased systolic blood pressure variability (BPV) during the acute period (2-24 hours postrandomization)
Number of subjects: 913
Study 30012822 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased systolic blood pressure variability (BPV) during the subacute period (days 2, 3, and 7)
Number of subjects: 913
Study 30012822 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure mean
Number of subjects: 913
Study 27418597 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg/d without loading dose) plus Aspirin (300 mg loading followed by 100 mg/d)
Number of subjects: 358
Study 27418597 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (300 mg loading followed by 100 mg/d)
Number of subjects: 358
Study 27418597 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus Aspirin
Number of subjects: 358
Study 27418597 — intervention group
Group type: COMPARATOR
Intervention: Aspirin monotherapy
Number of subjects: 358
Study 24556888 — intervention group
Group type: EXPERIMENTAL
Intervention: Theatre with floor drainage
Number of subjects: 1027
Study 24556888 — intervention group
Group type: COMPARATOR
Intervention: Theatre without floor drainage
Number of subjects: 1027
Study 23107508 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg of nicotine
Number of subjects: 0
Study 23107508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19767012 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro-constancy condition (fixed biological traits)
Number of subjects: 62
Study 19767012 — intervention group
Group type: COMPARATOR
Intervention: Anti-constancy condition (mutable biological traits)
Number of subjects: 62
Study 18386234 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.05 mg/kg IV (Group I)
Number of subjects: 30
Study 18386234 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine 0.3 mg/kg IV followed by midazolam 0.05 mg/kg IV (Group II)
Number of subjects: 30
Study 15925264 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based brief motivational intervention (motivation enhancement system, or MES)
Number of subjects: 80
Study 15925264 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 80
Study 12402990 — intervention group
Group type: EXPERIMENTAL
Intervention: R‐wave‐triggered imaging using a 7.5‐MHz ultrasound transducer with acquisition every 41.7‐66.7 ms
Number of subjects: 24
Study 12402990 — intervention group
Group type: COMPARATOR
Intervention: Ignoring temporal position within the cardiac cycle
Number of subjects: 24
Study 10436098 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (antiplatelet medication)
Number of subjects: 140
Study 10436098 — intervention group
Group type: COMPARATOR
Intervention: No aspirin (control group)
Number of subjects: 140
Study 7775993 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed feedback on prescribing profiles and treatment recommendations for insomnia and acute cystitis
Number of subjects: 0
Study 7775993 — intervention group
Group type: COMPARATOR
Intervention: Control group (GPs in Romsdal without feedback)
Number of subjects: 0
Study 1971855 — intervention group
Group type: EXPERIMENTAL
Intervention: Befunolol 0.5%
Number of subjects: 60
Study 1971855 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol 1%
Number of subjects: 60
Study 1971855 — intervention group
Group type: COMPARATOR
Intervention: NaCl 0.9% (Placebo)
Number of subjects: 60
Study 479383 — intervention group
Group type: EXPERIMENTAL
Intervention: Penbutolol 25 to 75 mg twice daily (group A)
Number of subjects: 30
Study 479383 — intervention group
Group type: EXPERIMENTAL
Intervention: Penbutolol 50 to 150 mg twice daily (group B)
Number of subjects: 30
Study 479383 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control period)
Number of subjects: 30
Study 31054396 — intervention group
Group type: EXPERIMENTAL
Intervention: Tree thinning treatments
Number of subjects: 0
Study 31054396 — intervention group
Group type: COMPARATOR
Intervention: Control plots
Number of subjects: 0
Study 29505422 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping skills training program
Number of subjects: 260
Study 29505422 — intervention group
Group type: COMPARATOR
Intervention: Education program
Number of subjects: 260
Study 26714939 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic Scalpel (USS)
Number of subjects: 80
Study 26714939 — intervention group
Group type: COMPARATOR
Intervention: Control (ligation and monopolar electrocautery)
Number of subjects: 80
Study 24598043 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon dilation of the maxillary sinuses/ethmoid infundibula with or without frontal or sphenoid ostial dilation
Number of subjects: 81
Study 24598043 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon dilation
Number of subjects: 81
Study 21728184 — intervention group
Group type: EXPERIMENTAL
Intervention: Functioning Improvement Tool (FIT) home-visit program for 3 months, 60 minutes per visit
Number of subjects: 199
Study 21728184 — intervention group
Group type: COMPARATOR
Intervention: Control group (no home visits)
Number of subjects: 199
Study 21728184 — intervention group
Group type: EXPERIMENTAL
Intervention: Functioning Improvement Tool (FIT) home-visit program for subjects with mild cognitive decline (baseline MMSE scores from 18 to 23 points)
Number of subjects: 199
Study 21728184 — intervention group
Group type: COMPARATOR
Intervention: Control group for subjects with mild cognitive decline
Number of subjects: 199
Study 20085915 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrolife culture medium
Number of subjects: 188
Study 20085915 — intervention group
Group type: COMPARATOR
Intervention: Cook culture medium
Number of subjects: 188
Study 17964399 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine LS 0.4% (Acular)
Number of subjects: 183
Study 17964399 — intervention group
Group type: COMPARATOR
Intervention: Nepafenac 0.1% (Nevanac)
Number of subjects: 183
Study 16098067 — intervention group
Group type: COMPARATOR
Intervention: CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone)
Number of subjects: 211
Study 16098067 — intervention group
Group type: EXPERIMENTAL
Intervention: CIOP (cyclophosphamide, idarubicin, vincristine and prednisolone)
Number of subjects: 211
Study 16098067 — intervention group
Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 211
Study 16098067 — intervention group
Group type: EXPERIMENTAL
Intervention: CIOP
Number of subjects: 211
Study 12190265 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser therapy
Number of subjects: 33
Study 12190265 — intervention group
Group type: COMPARATOR
Intervention: Standard surgery (transurethral resection of the prostate)
Number of subjects: 33
Study 12190265 — intervention group
Group type: COMPARATOR
Intervention: Conservative management (monitoring without active intervention)
Number of subjects: 33
Study 10909487 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute myocardial infarction
Number of subjects: 75
Study 10909487 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute myocardial ischemia
Number of subjects: 75
Study 10909487 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute myocardial ischemia and acute myocardial infarction
Number of subjects: 75
Study 10909487 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 75
Study 7601015 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin 200 mg or 400 mg once daily for uncomplicated urinary tract infections
Number of subjects: 0
Study 7601015 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin 200 mg or 400 mg single oral dose for gonorrhoea
Number of subjects: 0